|
Apr 24
|
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
|
|
Apr 24
|
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
|
|
Apr 24
|
Can Biogen Keep the Beat Streak Alive This Earnings Season?
|
|
Apr 24
|
Biogen’s Friedreich’s ataxia treatment authorised in UK
|
|
Apr 16
|
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
|
|
Apr 16
|
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
|
|
Apr 15
|
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
|
|
Apr 11
|
Alzheon’s Alzheimer’s pill fails in Phase III trial
|
|
Apr 10
|
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
|
|
Apr 10
|
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
|
|
Mar 14
|
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
|
|
Mar 14
|
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
|
|
Mar 12
|
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
|
|
Mar 12
|
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
|
|
Mar 11
|
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
|
|
Mar 3
|
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
|
|
Feb 28
|
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
|
|
Feb 25
|
Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts
|
|
Feb 24
|
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
|
|
Feb 19
|
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
|